RECORLEV

PeakSM

levoketoconazole

Bridge Therapeutics

NDAORALTABLET

Approved

Dec 2021

Lifecycle

Peak

Competitive Pressure

0/100

Mechanism of Action

Cytochrome P450 11B1 Inhibitors

Pharmacologic Class:

Cortisol Synthesis Inhibitor

Loss of Exclusivity

LOE Date

Mar 2, 2040

170 months away

Patent Expiry

Mar 2, 2040

Exclusivity Expiry

Dec 30, 2028

Patent Records (5)

Patent #	Expiry	Type	Use Code
11478471	Jan 10, 2026Expired		U-3283
10517868	Jan 10, 2026Expired		U-3283
10835530	Jan 10, 2026Expired		U-3283
10098877	Jan 10, 2026Expired		U-3283
9918984	May 3, 2028		U-3283

Company

Bridge Therapeutics

AL - Birmingham

External Resources

Full prescribing information

FDA approval history